Hepatitis B virus-related hepatocellular carcinoma


Introduction

Main liver most cancers is the sixth most incessantly identified most cancers and the third most deadly most cancers, with roughly 906,000 new circumstances and 830,000 deaths worldwide.1 The incidence of liver most cancers is rising all around the world.2,3 It’s estimated that by 2025, greater than 1 million individuals worldwide might be affected by liver most cancers yearly.2 Hepatocellular carcinoma (HCC) is the commonest kind of liver most cancers, accounting for roughly 90% of the full variety of circumstances.2 HBV an infection is an important danger issue for HCC, accounting for roughly 50% of circumstances.4 The annual incidence of HCC in individuals with HCV-related cirrhosis ranges from 0.5–10%.1 Between 10% and 20% of HCC circumstances within the USA are actually attributed to Non-alcoholic fatty liver illness (NAFLD).5 The developments of alcohol use and alcoholic liver illness range amongst international locations. Liver cirrhosis (LC) related to HBV an infection is a key danger issue for tumorigenesis.6

Early prognosis of HCC is carefully associated to its prognosis.7 Though imaging strategies akin to ultrasound and magnetic resonance imaging (MRI) enormously enhance the diagnostic accuracy of HCC, their functions are restricted due to insensitivity to small tumors.8 Among the many non-invasive biomarkers, alpha-fetoprotein (AFP) and protein induced by vitamin Okay absence or antagonist II (PIVKA-II) have been broadly studied in hepatocellular carcinoma.9–12 AFP is a conventional serum marker for HCC, however its diagnostic accuracy is proscribed due to its excessive false-negative detection fee in small and early tumors. AFP ranges are elevated in non-HCC illnesses akin to LC, hepatitis, and cholangiocarcinoma, and the marker lacks specificity.13 Subsequently, AFP alone just isn’t beneficial as a major screening take a look at for HCC.14

Throughout the malignant transformation of hepatocytes, the vitamin Okay-dependent carboxylase system is broken, leading to a carboxylation dysfunction of the N-terminal glutamate residues of the coagulation issue. This irregular coagulation issue, PIVKA-II (also referred to as de-γ-carboxyprothrombin), loses the power to carry out the clotting perform.15 In a meta-analysis, whatever the measurement of the tumor, the ethnic background of the affected person (United States, Europe, Asia, or Africa), or the etiology of HCC (HBV-related or blended), PIVKA-II enabled extra correct detection of HBV-related HCC than AFP.16

D-D is a product of fibrin degradation. An elevated degree of D-D signifies the presence of hypercoagulable states and secondary hyperfibrinolysis, which primarily displays the fibrinolytic perform of the physique.17 Rising proof exhibits that there’s a relationship between coagulation activation and tumor angiogenesis, development, and metastasis.18,19 Research have proven that D-D could also be a possible diagnostic index of HCC and can be utilized as a easy and efficient predictor of poor tumor traits and prognosis of HCC.17,20

On this research, we investigated whether or not the mixed detection of D-D, PIVKA-II, and AFP has a greater diagnostic worth for HBV-related HCC than single-protein detection.

Supplies and Strategies

Sufferers

A complete of 291 sufferers admitted to the First Affiliated Hospital of Hunan Regular College from Could 2020 to Could 2021 have been chosen, together with 148 sufferers with HBV-related HCC and 143 sufferers with HBV-related LC. Among the many 148 sufferers with HCC, 59 had early-stage HCC, and 89 had superior HCC. Amongst sufferers with superior HCC, 63 sufferers had vascular invasion, distant metastasis, or lymph node invasion. Among the many 148 sufferers with HCC, 72 had HBV DNA+ HCC, and 76 had HBV DNA- HCC. HBV-related LC sufferers have been divided into the next classes: HBV DNA+ LC (n = 63) and HBV DNA- LC (n = 70). The prognosis of HBV-related HCC was primarily based on the diagnostic standards of the Pointers of Chinese language Society of Medical Oncology Hepatocellular Carcinoma (2020).21 The primary diagnostic standards are as follows: 1) a historical past of major liver illnesses, akin to continual hepatitis or cirrhosis; 2) elevated AFP, particularly with a markedly progressive elevation of AFP; 3) at the very least two imaging exams to help the prognosis of liver most cancers, akin to enhanced MRI, enhanced CT, colour Doppler ultrasound, and so on; 4) take a biopsy of atypical liver nodules, and most cancers cells have been discovered beneath the microscope.21 Early-stage HCC was outlined because the presence of just one tumor lower than or equal to five.0 cm within the liver with out vascular infiltration or extrahepatic metastasis.21 LC prognosis was made in accordance with the Chinese language tips for the administration of LC.22 The prognosis of compensated liver cirrhosis is predicated on the next: 1) Histology is in line with the prognosis of liver cirrhosis; (2) Endoscopy exhibits esophagogastric varices or gastrointestinal varices, excluding non-cirrhotic venous hypertension; (3) B-ultrasound or CT Different imaging examinations recommend the traits of liver cirrhosis or venous hypertension; (4) irregular liver perform and different take a look at indicators recommend the existence of liver cirrhosis. Primarily based on liver cirrhosis, problems of portal hypertension and/or decreased liver perform might be identified as decompensated liver cirrhosis.22 The prognosis of HBV an infection was primarily based on the Hepatitis B floor antigen and Hepatitis B virus DNA. Tumor measurement was measured by dynamic contrast-enhanced MRI or dynamic contrast-enhanced CT scan, mixed with the scale of the tumor specimen after surgical resection.

Measurement of PIVKA-II, AFP, D-D, and HBV DNA Ranges

The serum ranges of PIVKA II and AFP have been detected by electrochemiluminescence immunoassay (Abbott i2000; Abbott Laboratories, USA). D-D ranges have been measured by turbidimetric inhibition immunoassay (Coatron 5000; TECO, Inc., Germany). The concentrations of PIVKA-II, AFP, and D-D have been measured by way of mAU/mL, ng/mL, and μg/L, respectively. HBV DNA ranges have been decided utilizing real-time polymerase chain response (Gentle-Cycler 480II; Roche, Inc.). Concentrations of HBV DNA ≥ 500 IU/mL have been thought-about optimistic (HBV DNA+); < 500 IU/mL, damaging (HBV DNA-).

Statistical Evaluation

Statistical analyses have been carried out utilizing SPSS 26.0 (IBM, USA). Information are expressed because the median (interquartile vary) or proportion (%). The Mann–Whitney U-test was used to guage the variations between the 2 teams. Pearson’s chi-square take a look at was used to match the sexes. The Spearman rank correlation coefficient (rs) was used to guage the correlation between steady variables. Receiver working attribute (ROC) curve evaluation was carried out to estimate the worth of PIVKA-II, AFP, and D-D, and the realm beneath the curve (AUC), 95% confidence interval (CI), and corresponding diagnostic sensitivity and specificity have been additionally calculated. DeLong’s take a look at was used to match the variations among the many AUCs. P < 0.05 was thought-about statistically important.

Outcomes

Examine Traits

A complete of 291 sufferers (148 HCC sufferers and 143 LC sufferers) have been enrolled. The scientific options are proven in Desk 1. The age of HCC sufferers was considerably larger than that of LC sufferers (55 vs 51 years; P < 0.05). The sufferers in each teams have been predominantly male (89% of HCC sufferers (131/148) and 77% of LC sufferers (110/143); P = 0.009). The serum ranges of PIVKA-II and AFP in HCC sufferers have been considerably larger than these in LC sufferers (P < 0.001). In distinction, the D-D degree in HCC sufferers was decrease than that in LC sufferers (P < 0.001).

Desk 1 Traits of the Sufferers Included within the Examine

PIVKA-II, AFP, and D-D Ranges in LC, Early-Stage HCC, and Superior HCC Sufferers

The degrees of PIVKA-II, AFP, and D-D in HCC sufferers have been positively correlated with tumor measurement (rs= 0.543, P < 0.001; rs = 0.331, P < 0.001; rs = 0.425, P < 0.001; Determine 1A–C). The degrees of PIVKA-II, AFP, and D-D in sufferers with early-stage HCC have been considerably decrease than these in sufferers with superior HCC (P < 0.001, P < 0.01, P < 0.001). Serum ranges of PIVKA-II and AFP within the HCC group have been larger than these within the LC group (P < 0.001, P < 0.05; Determine 1D–E), whereas D-D ranges within the HCC group have been decrease (P < 0.001, Determine 1F).

Determine 1 Evaluation of PIVKA-II, AFP, and D-D. (AC) Correlations between PIVKA-II, AFP, and D-D with tumor measurement; (DF) Comparability of PIVKA-II, AFP, and D-D ranges in early-stage HCC sufferers, superior HCC sufferers, and LC sufferers (*P<0.5; **P<0.01; ***P<0.001).

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; PIVKA-II, protein induced by vitamin Okay absence or antagonist II; AFP, alpha-fetoprotein; D-D, D-dimer.

Diagnostic Worth of Single-Index and Mixed Detection of PIVKA-II, AFP, and D-D

For the comparability of early-stage HCC and LC sufferers, PIVKA-II exhibited the perfect diagnostic worth (AUC = 0.871), adopted by D-D (AUC = 0.837) and AFP (AUC = 0.599) (Determine 2A; Desk 2). When pairwise mixed detection was carried out, PIVKA-II + D-D demonstrated the perfect efficiency (AUC = 0.957), and the diagnostic worth was larger than that of single-index detection. The AUC of three-index mixed detection was 0.957, which was larger than that of PIVKA-II + AFP (AUC = 0.863; P < 0.001; Determine 2B; Desk 2). For the comparability of sufferers with superior HCC and LC, PIVKA-II once more demonstrated the perfect single-index diagnostic worth (AUC = 0.929; Determine 2C; Desk 2), and PIVKA-II + D-D demonstrated the perfect outcome (AUC = 0.958) for pairwise mixed detection. The AUC of the three mixed markers was 0.960, larger than that of PIVKA-II + AFP mixed detection (P < 0.001; Determine 2D; Desk 2).

Desk 2 Efficiency Worth of PIVKA-II, AFP, and D-D in Sufferers with Early-Stage HCC and Superior HCC

Determine 2 ROC curves of PIVKA-II, AFP, and D-D, and their mixtures in HCC sufferers. (A and B) ROC curves of PIVKA-II, AFP, and D-D, and their mixtures in early-stage HCC sufferers, LC sufferers served as controls; (C and D) ROC curves of PIVKA-II, AFP, and D-D, and their mixtures in superior HCC sufferers, LC sufferers served as controls.

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; PIVKA-II, protein induced by vitamin Okay absence or antagonist II; AFP, alpha-fetoprotein; D-D, D-dimer.

Diagnostic Worth of PIVKA-II, AFP, and D-D in HBV DNA- HCC and HBV DNA+ HCC Sufferers

Serum ranges of PIVKA-II and AFP in HBV DNA- or HBV DNA+ HCC sufferers have been larger than these in HBV DNA- or HBV DNA+ LC sufferers (P < 0.001), whereas the extent of D-D in HCC sufferers was decrease (P < 0.001; Determine 3A–C; Determine 4A–C).

Determine 3 Diagnostic worth of PIVKA-II, AFP, and D-D in HBV DNA- HCC. (AC) PIVKA-II, AFP, and D-D have been in contrast between HBV DNA- HCC sufferers and LC sufferers. (D) ROC curves of PIVKA-II, AFP, and D-D of sufferers with HCC who have been damaging for HBV DNA. Sufferers with liver cirrhosis have been used as controls. (E) ROC curves of PIVKA-II, AFP, and D-D mixed with HBV DNA – HCC sufferers. Sufferers with cirrhosis served as controls (***P<0.001).

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; PIVKA-II, protein induced by vitamin Okay absence or antagonist II; AFP, alpha-fetoprotein; D-D, D-dimer.

Determine 4 Diagnostic worth of PIVKA-II, AFP, and D-D in HBV DNA+ HCC. (AC) PIVKA-II, AFP, and D-D have been in contrast between HBV DNA+ HCC sufferers and LC sufferers. (D) ROC curves of PIVKA-II, AFP, and D-D of sufferers with HCC who have been optimistic for HBV DNA. Sufferers with liver cirrhosis have been used as controls. (E) ROC curves of PIVKA-II, AFP, and D-D mixed with HBV DNA optimistic HCC sufferers. Sufferers with cirrhosis served as controls (***P<0.001).

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; PIVKA-II, protein induced by vitamin Okay absence or antagonist II; AFP, alpha-fetoprotein; D-D, D-dimer.

In HBV DNA- HCC sufferers, the AUCs of PIVKA-II, AFP, and D-D have been 0.866 (95% CI: 0.805–0.926), 0.731 (95% CI: 0.648–0.815), and 0.821 (95% CI: 0.749–0.893), respectively (Determine 3D). In HBV DNA+ HCC sufferers, the AUCs of PIVKA-II, AFP, and D-D have been 0.936 (95% CI: 0.901–0.971), 0.700 (95% CI: 0.612–0.788), and 0.689 (95% CI: 0.606–0.772), respectively (Determine 4D). The AUC of PIVKA-II in HBV DNA- HCC sufferers was decrease than that in HBV DNA+ HCC sufferers (0.866 vs 0.936), whereas the AUC of AFP in HBV DNA- HCC sufferers was larger (0.731 vs 0.700).

In HBV DNA+ HCC and HBV DNA- HCC sufferers, when PIVKA-II, AFP, and D-D have been detected collectively, the AUC was larger than it was for the single-index exams (Figures 3E and 4E). Nonetheless, there was no important distinction within the AUC between HBV DNA+ HCC and HBV DNA- HCC sufferers. The diagnostic efficiency of PIVKA-II, AFP, and D-D in HBV DNA+ and HBV DNA- HCC is proven in Desk 3.

Desk 3 Diagnostic Accuracy of PIVKA-II, AFP, and D-D in HBV DNA Detrimental or HBV DNA Optimistic HCC Sufferers

Dialogue

Early prognosis of HCC is essential for bettering the survival fee. Subsequently, systematic screening of high-risk teams is critical. At current, HCC-related biomarkers have been broadly studied to enhance the prognosis of early-stage HCC in sufferers with LC.9,23 AFP is a generally used biomarker for HCC, however its sensitivity and specificity will not be passable, particularly within the prognosis of early-stage HCC.24

Subsequently, it’s mandatory to mix serological markers for the early prognosis of high-risk sufferers. PIVKA-II, irregular prothrombin, is a particular marker for HCC. Earlier research have proven that its diagnostic sensitivity and specificity are superior to these of AFP.25,26 D-D is a vital index that displays the blood coagulation state of the physique. Within the technique of malignant tumors, as a result of infiltration, metastasis, and destruction of tumor cells, numerous procoagulant substances enter the blood, inflicting the physique to enter a hypercoagulable state.27 Subsequently, we evaluated whether or not D-D can be utilized as a diagnostic marker for HBV-related HCC and whether or not the diagnostic accuracy is improved when D-D is detected together with PIVKA-II and AFP.

The degrees of PIVKA-II, AFP, and D-D in sufferers with HBV-related HCC have been considerably completely different from these in sufferers with HBV-related LC. When PIVKA-II, AFP, and D-D have been used individually to detect HCC, the diagnostic worth of PIVKA-II was higher than that of AFP and D-D, in line with the findings of Xu et al.28 The diagnostic worth of D-D for the prognosis of early-stage HCC is healthier than that of AFP. In early-stage and superior HCC, the AUCs of PIVKA-II as a single index have been 0.871 and 0.929, respectively, and the AUCs of PIVKA-II mixed with AFP have been 0.863 and 0.932, respectively. There was no important enchancment within the diagnostic worth, which isn’t in line with the findings of Si et al.29 The explanation for this can be that LC sufferers comprised the management group in our research; some LC sufferers have various levels of improve in AFP ranges as a result of hepatocyte regeneration, whereas some sufferers with HCC don’t secrete AFP.

We additionally seen that PIVKA-II and AFP ranges have been positively correlated with HCC tumor measurement (Determine 1A and B), which is a vital motive why the diagnostic worth of PIVKA-II and AFP in early-stage HCC was decrease than that in superior HCC. The diagnostic worth of PIVKA-II and D-D in early-stage HCC was considerably larger than that of AFP, and the diagnostic worth of mixed detection was larger than that of single-index detection. Subsequently, serum D-D and PIVKA-II ranges can be utilized for the prognosis of early-stage liver most cancers.

The serum ranges of PIVKA-II and AFP in sufferers with HBV DNA+ HCC and HBV DNA+ LC have been considerably larger than these in sufferers with HBV DNA- HCC and HBV DNA- LC, respectively, which was in line with the outcomes of Wang et al.12 It’s advised that the replication of HBV might improve the expression of PIVKA-II and AFP in irregular hepatocytes. This will likely even be the principle motive why the cut-off of HBV DNA+ HCC (> 646.1 ng/mL) is considerably bigger than that of HBV DNA- HCC (> 11.85 ng/mL).

Within the single-index detection take a look at, the diagnostic worth of PIVKA-II was the very best, adopted by that of D-D and AFP. Within the pairwise mixed detection exams, the diagnostic values of PIVKA-II + D-D and AFP + D-D have been larger than these of PIVKA-II and AFP, suggesting that the addition of D-D was useful. As well as, the diagnostic worth of PIVKA-II in HBV DNA+ HCC was larger than that in HBV DNA- HCC. The AUC of AFP in sufferers with HBV DNA- HCC was larger than that in sufferers with HBV DNA+ HCC; due to this fact, PIVKA-II had the strongest diagnostic capability in HBV DNA+ HCC, whereas AFP had the strongest diagnostic capability in HBV DNA- HCC. The mixed detection of PIVKA-II, AFP, and D-D can enhance the diagnostic worth for various kinds of HCC.

We additionally discovered that the extent of D-D in HCC sufferers was decrease than that in LC sufferers. Fibrinogen is an acute-phase reactant produced by the liver throughout uncontrollable tumor or systemic irritation, and D-D is a degradation product of fibrin; due to this fact, D-D ranges improve with a rise in fibrinolysis.30,31 Therefore, in LC sufferers, the destruction of regular liver perform weakens the power of the liver to provide fibrinogen, and D-D ranges improve considerably. Conversely, in HCC sufferers, on account of the response to malignant tumors, the rise within the D-D degree is smaller than that in LC sufferers. Our outcomes additionally confirmed that the D-D degree was positively correlated with tumor measurement, suggesting that D-D is just like PIVKA-II and AFP and is one other indicator of HCC development. Subsequently, it’s mandatory to research the function of D-D within the development and prognosis of HCC sufferers. Nonetheless, our research didn’t embody an in depth staging system for superior HCC, which must be additional investigated by follow-up experiments.

Conclusion

In conclusion, D-D could also be a helpful biomarker for the prognosis of early-stage HCC. PIVKA-II and AFP exhibited the perfect diagnostic worth in HBV DNA+ HCC and HBV DNA- HCC, respectively. In comparison with single-index detection, the mixed detection of PIVKA-II, AFP, and D-D demonstrated improved diagnostic worth for various kinds of HCC.

Ethics Approval and Knowledgeable Consent

This analysis was permitted by the Moral Committee of Hunan Provincial Individuals’s Hospital (The First Affiliated Hospital of Hunan Regular College) and strictly following the Declaration of Helsinki (approval quantity: 2021 Scientific Analysis Ethics Evaluate NO 79). The information are nameless, and the requirement for knowledgeable consent was due to this fact waived.

Writer Contributions

All authors made a big contribution to the work reported, whether or not that’s within the conception, research design, execution, acquisition of knowledge, evaluation, and interpretation, or in all these areas; took half in drafting, revising or critically reviewing the article; gave last approval of the model to be printed; have agreed on the journal to which the article has been submitted, and conform to be accountable for all points of the work.

Funding

This work was supported by Nationwide Improvement and Reform Fee Challenge (No. 2019X000M045).

Disclosure

The authors declare that there isn’t a battle of curiosity concerning the publication of this paper.

References

1. Zhang CH, Cheng Y, Zhang S, et al. Altering epidemiology of hepatocellular carcinoma in Asia. Liver Int. 2022. doi:10.1111/liv.15251

2. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3

3. Longerich T. Hepatocellular carcinoma. Pathologe. 2020;41(5):478–487. doi:10.1007/s00292-020-00801-z

4. Akinyemiju T, Abera S, Ahmed M, et al. The burden of major liver most cancers and underlying etiologies from 1990 to 2015 on the international, regional, and nationwide degree: outcomes from the worldwide burden of illness research 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055.

5. Yang JD, Hainaut P, Gores GJ, et al. A worldwide view of hepatocellular carcinoma: developments, danger, prevention and administration. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y

6. Marrero JA, Kulik LM, Sirlin CB, et al. Analysis, staging, and administration of hepatocellular carcinoma: 2018 follow steering by the American affiliation for the research of liver illnesses. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913

7. Singal AG, Pillai A, Tiro J. Early detection, healing therapy, and survival charges for hepatocellular carcinoma surveillance in sufferers with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi:10.1371/journal.pmed.1001624

8. Feng H, Li B, Li Z, et al. PIVKA-II serves as a possible biomarker that enhances AFP for the prognosis of hepatocellular automobile cinoma. BMC Most cancers. 2021;21(1):401. doi:10.1186/s12885-021-08138-3

9. Caviglia GP, Ciruolo M, Abate ML, et al. Alpha-fetoprotein, protein induced by vitamin Okay absence or antagonist II and glypican-3 for the detec tion and prediction of hepatocellular carcinoma in sufferers with cirrhosis of viral etiology. Cancers. 2020;12(11):11. doi:10.3390/cancers12113218

10. Su TH, Peng CY, Chang SH, et al. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in continual hepatitis B associated cirrhosis. J Formos Med Assoc. 2021;121(3):703–711. doi:10.1016/j.jfma.2021.08.003

11. Caviglia GP, Armandi A, Rosso C, et al. Biomarkers of oncogenesis, adipose tissue dysfunction and systemic irritation for the detection of hepatocellular carcinoma in sufferers with nonalcoholic fatty liver illness. Cancers. 2021;13(10):10. doi:10.3390/cancers13102305

12. Wang Q, Chen Q, Zhang X, et al. Diagnostic worth of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vi tamin Okay absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2019;25(36):5515–5529. doi:10.3748/wjg.v25.i36.5515

13. Inoue T, Tanaka Y. Novel biomarkers for the administration of continual hepatitis B. Clin Mol Hepatol. 2020;26(3):261–279. doi:10.3350/cmh.2020.0032

14. Ayoub WS, Steggerda J, Yang JD, et al. Present standing of hepatocellular carcinoma detection: screening methods and novel biomarkers. Ther Adv Med Oncol. 2019;11:1758835919869120. doi:10.1177/1758835919869120

15. Xu JF, Liu XY. PIVKA-II is an unbiased prognostic issue for total survival of HCC sufferers and possibly affiliate d with epithelial-mesenchymal transition. J Hepatol. 2015;63(4):1040–1041. doi:10.1016/j.jhep.2015.04.031

16. Chen J, Wu G, Li Y. Analysis of serum des-gamma-carboxy prothrombin for the prognosis of hepatitis B virus-related hepa tocellular carcinoma: a meta-analysis. Dis Markers. 2018;2018:8906023. doi:10.1155/2018/8906023

17. Liu Z, Guo H, Gao F, et al. Fibrinogen and D-dimer ranges elevate in superior hepatocellular carcinoma: excessive pretreatment fibrino gen ranges predict poor outcomes. Hepatol Res. 2017;47(11):1108–1117. doi:10.1111/hepr.12848

18. Zhu LR, Li J, Chen P, et al. Medical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and pr ognosis for small cell lung most cancers sufferers. Clin Transl Oncol. 2016;18(2):178–188. doi:10.1007/s12094-015-1350-7

19. Man YN, Wang YN, Hao J, et al. Pretreatment plasma D-dimer, fibrinogen, and platelet ranges considerably influence prognosis in patien ts with epithelial ovarian most cancers independently of venous thromboembolism. Int J Gynecol Most cancers. 2015;25(1):24–32. doi:10.1097/IGC.0000000000000303

20. Jing W, Peng R, Zhu M, et al. Differential expression and diagnostic significance of pre-albumin, fibrinogen mixed with D-Dimer in AFP-negative hepatocellular carcinoma. Pathol Oncol Res. 2020;26(3):1669–1676. doi:10.1007/s12253-019-00752-8

21. Chinese language Society of Medical Oncology. Pointers of Chinese language Society of Medical Oncology (CSCO) hepatocellular Carcinoma. China: Individuals’s Medical Publishing Home; 2020.

22. Chinese language Society of Hepatology. Chinese language tips on the administration of liver cirrhosis. Chin J Hepatol. 2019;27(11):846–865. doi:10.3760/cma.j.issn.1007-3418.2019.11.008

23. Yang T, Xing H, Wang G, et al. A novel on-line calculator primarily based on serum biomarkers to detect hepatocellular carcinoma amongst sufferers with hepatitis B. Clin Chem. 2019;65(12):1543–1553. doi:10.1373/clinchem.2019.308965

24. Wang G, Lu X, Du Q, et al. Diagnostic worth of the γ-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin Okay absence or antagonist II in hepatitis B virus-related hepatocellular ca rcinoma. Sci Rep. 2020;10(1):13519. doi:10.1038/s41598-020-70241-5

25. Svobodova S, Karlikova M, Topolcan O, et al. PIVKA-II as a possible new biomarker for hepatocellular carcinoma – A pilot research. In Vivo. 2018;32(6):1551–1554. doi:10.21873/invivo.11413

26. Search engine optimisation SI, Kim HS, Kim WJ, et al. Diagnostic worth of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular automobile cinoma. World J Gastroenterol. 2015;21(13):3928–3935. doi:10.3748/wjg.v21.i13.3928

27. Hou C, Jiang F, Ma H, et al. Prognostic function of preoperative platelet, fibrinogen, and D-dimer ranges in sufferers with non-small c ell lung most cancers: a multicenter potential research. Thorac Most cancers. 2019;10(2):304–311. doi:10.1111/1759-7714.12956

28. Xu F, Zhang L, He W, et al. The diagnostic worth of serum PIVKA-II alone or together with AFP in Chinese language hepatocellular carcinoma sufferers. Dis Markers. 2021;2021:8868370. doi:10.1155/2021/8868370

29. Si YQ, Wang XQ, Fan G, et al. Worth of AFP and PIVKA-II in prognosis of HBV-related hepatocellular carcinoma and prediction of vasc ular invasion and tumor differentiation. Infect Agent Most cancers. 2020;15(1):70. doi:10.1186/s13027-020-00337-0

30. Zhang PP, Solar JW, Wang XY, et al. Preoperative plasma D-dimer ranges predict survival in sufferers with operable non-small cell lung can cer independently of venous thromboembolism. Eur J Surg Oncol. 2013;39(9):951–956. doi:10.1016/j.ejso.2013.06.008

31. Ay C, Dunkler D, Pirker R, et al. Excessive D-dimer ranges are related to poor prognosis in most cancers sufferers. Haematologica. 2012;97(8):1158–1164. doi:10.3324/haematol.2011.054718



Supply hyperlink

Leave a Comment

 - 
Arabic
 - 
ar
Bengali
 - 
bn
English
 - 
en
French
 - 
fr
German
 - 
de
Indonesian
 - 
id
Portuguese
 - 
pt
Russian
 - 
ru
Spanish
 - 
es
Urdu
 - 
ur
%d bloggers like this: